- Conditions
- Hypoglycemia
- Interventions
- G-Pen Mini™ (glucagon injection)
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1897–1920
of 29,139
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma
- Interventions
- IFNα2b, PEG- IFNα2b
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Oncology
- Interventions
- BAY94-9343, BAY94-9343 (Expansion), BAY94-9343 (1.8 mg/kg), BAY94-9343 (2.2 mg/kg)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Bethesda, Maryland + 5 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- IMCY-0098 450 μg, IMCY-0098 1350 μg, Placebo
- Drug
- Lead sponsor
- Imcyse SA
- Industry
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 1 more
- Conditions
- Hepatitis C
- Interventions
- Not listed
- Lead sponsor
- Tacere Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Interventions
- Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Macon, Georgia • Austin, Texas • Bellaire, Texas + 2 more
- Conditions
- Osteosarcoma
- Interventions
- Avelumab, Questionnaires
- Drug · Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Years to 49 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New York, New York • Memphis, Tennessee + 1 more
- Conditions
- Amoebiasis
- Interventions
- Auranofin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Pruritus
- Interventions
- Obeticholic acid, Linerixibat
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction, Asthma, Wheezing, Influenza
- Interventions
- Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine (IIV)
- Biological
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Cincinnati, Ohio • Nashville, Tennessee
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Efpeglenatide SAR439977, Placebo, Background therapy: Metformin alone or in combination with SU
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 20 more
- Conditions
- Multiple Sclerosis
- Interventions
- ACT-128800 Dose 1, Placebo, ACT-128800 Dose 2, ACT-128800 Dose 3
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 22 more
- Conditions
- HIV Infections
- Interventions
- Lopinavir/Ritonavir, Emtricitabine, Stavudine
- Drug
- Lead sponsor
- Triangle Pharmaceuticals
- Industry
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more
- Conditions
- Non-Transfusion Dependent Beta-Thalassemia (NTDT)
- Interventions
- REGN7999, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Stable Coronary Artery Disease
- Interventions
- Ticagrelor, Clopidogrel, Aspirin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- Selitrectinib (BAY2731954)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
- Conditions
- Neuroblastoma
- Interventions
- Nifurtimox
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Burlington, Vermont
- Conditions
- AML, ALL, Blast Crisis, MDS, Multiple Myeloma
- Interventions
- TG02 citrate, Carfilzomib, Dexamethasone
- Drug
- Lead sponsor
- Tragara Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more
- Conditions
- Newly Diagnosed Ewing Sarcoma
- Interventions
- Cyclophosphamide, Doxorubicin, Vincristine, Ifosfamide, Etoposide, Surgery, Radiation Therapy*, Temozolomide, Irinotecan, Mesna, Dexrazoxane, G-CSF
- Drug · Device · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 1 Year to 40 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Exudative Age Related Macular Degeneration
- Interventions
- Sirolimus, EYLEA
- Drug
- Lead sponsor
- Maturi, Raj K., M.D., P.C.
- Individual
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- NXC-201 CAR-T
- Biological
- Lead sponsor
- Nexcella Inc.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 18
- States / cities
- Berkeley, California • Duarte, California • Los Angeles, California + 14 more
- Conditions
- Advanced Cancer
- Interventions
- MGCD265
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 12
- States / cities
- Duarte, California • Orange, California • San Diego, California + 9 more
- Conditions
- New Onset Atrial Fibrillation, Severe Sepsis, Septic Shock
- Interventions
- Amiodarone
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hemophilia B
- Interventions
- CSL222 (AAV5-hFIXco-Padua)
- Genetic
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 4
- States / cities
- San Diego, California • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more